1473 IMMEDIATE MITOMYCIN C INSTILLATION FOLLOWED BY USUAL BCG COURSE VERSUS USUAL BCG ALONE FOR SUPERFICIAL TRANSITIONAL CELL CARCINOMA OF THE BLADDER (4 YEARS EXPERIENCE)

Abstract

You have accessJournal of UrologyBladder Cancer: Superficial II1 Apr 20101473 IMMEDIATE MITOMYCIN C INSTILLATION FOLLOWED BY USUAL BCG COURSE VERSUS USUAL BCG ALONE FOR SUPERFICIAL TRANSITIONAL CELL CARCINOMA OF THE BLADDER (4 YEARS EXPERIENCE) Osman Abd El Kader Osman Abd El KaderOsman Abd El Kader More articles by this author View All Author Informationhttps://doi.org/10.1016/j.juro.2010.02.1188AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookTwitterLinked InEmail INTRODUCTION AND OBJECTIVES we present our experience with combination of chemo-immunotherapy fËmitomycin (MMC) + Bacillus Callmette ¡VGuerin (BCG) fÍ in comparison to single agent BCG immunotherapy as regard efficacy and side effects for superficial cancer bladder transitional cell carcinoma TCC with 6 months follow up at least. METHODS between July 2004 and June 2008, 128 patients (86 men and 42 women) with histologically proven bladder TCC and a mean age of 54 years were included into this prospective study, the definitive stage was Ta in 5 patients and T1 in 123 patients, while thegrade was grade I in 18, grade II in 86 patients and grade III in 24 patients, all patients underwent transurethral resection of the bladder tumor (TURBT) then randomly divided into two groups, group one 68 patients received immediate 40 mg mitomycinC (MMC) followed by BCG weekly for 6 weeks 3 weeks post TURBT, group two 60 patients underwent BCG instillation weekly for 6 weeks post TURBT by 3 weeks with follow up cystoscopy. RESULTS follow up ranged from 6-45 months with a mean of 26 months. Out of the group 1, 43 patients (63 %) were free at last follow up, 17 (25 %) showed recurrence and 8 (12%) showed muscle invasive progression and in group 2; 27 patients (45%) were free at last follow up, 20 (33%) showed recurrence and 13 (22%) showed muscle invasive progression. The mean interval to recurrence was 15 months range (3-45) in group 1 and 13 months range (3-45) in group 2 and the mean interval to progression in group 1 was 18 months (range 3-45) and in group 2 was 15 months range (3-45), Side effect of intravesical instillation distributed in both groups approximately in the same level, in group I; 20 patients (30%) with post instillation symptoms in the form of lower urinary tract symptoms (LUTS) in 14 patients (21%), 2 patients (3%) epidydmitis, 2 patients (3%) by hematuria and 2 patients (3%) presented by fever, chills and flue like symptoms, in group II 18 patients (30%) presented by post instillation symptoms in the form of (LUTS) in 12 patients (20%), one patients (1.5%) epidydmitis, 2 patients (3.5%) by hematuria and 3 patients (5%) presented by fever, chills and flue like symptoms. CONCLUSIONS the efficacy of chemo-immunotherapy in superficial cancer bladder TCC is evident over immunotherapy alone however side effects not appear to be increased however multicenter trial was indicated to consolidate these results. Fakous, Egypt© 2010 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 183Issue 4SApril 2010Page: e567-e568 Advertisement Copyright & Permissions© 2010 by American Urological Association Education and Research, Inc.MetricsAuthor Information Osman Abd El Kader More articles by this author Expand All Advertisement Advertisement PDF downloadLoading ...